2026-01-23 - Analysis Report
**Company Overview**
Novo Nordisk is a multinational pharmaceutical company focused on developing and manufacturing innovative treatments for patients with significant unmet medical needs.

**Return Rate Comparison**

| Ticker | Company Name | Cumulative Return | Divergence | Relative Divergence |
| --- | --- | --- | --- | --- |
| NVO (Review) | Novo Nordisk | 53.06% | -40.10 | 19.30% |
| S&P 500 (VOO) | Comparison | 92.53% |  |  |

Note: The divergence is calculated as the difference in cumulative return on the last day of the data.

**Alpha, Beta Analysis**

| Year | CAGR | MDD | Alpha | Beta | Market Capitalization (B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 0.0% | 19.0% | -5.0% | 0.8 | 102.4B |
| 2017-2019 | 37.0% | 13.6% | 20.0% | 0.6 | 128.6B |
| 2018-2020 | 1.0% | 12.5% | -20.0% | 0.6 | 155.2B |
| 2019-2021 | 58.0% | 13.0% | 15.0% | 0.6 | 248.8B |
| 2020-2022 | 58.0% | 23.2% | 60.0% | 0.6 | 300.7B |
| 2021-2023 | 87.0% | 23.2% | 86.0% | 0.5 | 459.7B |
| 2022-2024 | 18.0% | 40.5% | -1.0% | 0.5 | 382.2B |
| 2023-2025 | -52.0% | 59.7% | -114.0% | 0.7 | 226.1B |

**Recent Stock Price Fluctuations**

|  | Value |
| --- | --- |
| Close | $62.23 |
| Last-market | $62.23 |
| Previous Close | $59.32 |
| Change | 4.91 |
| 5-day SMA | $60.34 |
| 20-day SMA | $56.34 |
| 60-day SMA | $51.11 |

**RSI, PPO Index Indicators, and Delta**

| Indicator | Value |
| --- | --- |
| RSI | 74.84 |
| PPO | 0.58 |
| Hybrid Signal | Buy (Cash 0%) |
| Risk Level | High (MRI 0.90) |
| Recent (20 days) relative divergence change | 3.50 (+): improving |
| 7-day Rank change | 20 (+): rank up |
| 7-day Dynamic Expected Return change | -143.50 (-): worsening |

**Expected Return**
216.00% (Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.)

**Recent News & Significant Events**

* Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
* Novo Nordisk: NVO Stock To $100? - Forbes
* Warning: This Skyrocketing Stock Has a Hidden Risk - The Motley Fool
* Novo Nordisk A/S $NVO Shares Sold by Boston Common Asset Management LLC - MarketBeat
* ‘Sales and Earnings to Shrink in 2026’ TD Cowen Says of Novo Nordisk Stock (NVO) - TipRanks
* Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Jan 2026) - 24/7 Wall St.

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
- Opinions: 11
- Target Price (avg/high/low): 57.69 / 74.16 / 42.09

**Comprehensive Analysis**

Summary:

Novo Nordisk's cumulative return is 53.06%, while the comparison S&P 500 (VOO) has a cumulative return of 92.53%. The divergence is -40.10, indicating the review stock has underperformed compared to the S&P 500 in the provided data.

The Alpha, Beta analysis indicates that the company has had varying levels of performance across different periods, with a relatively stable Beta and fluctuating Alpha values.

Recent stock price fluctuations show a sharp rebound, with a 5-day SMA of $60.34 and a 20-day SMA of $56.34.

Indicators such as RSI, PPO, and Hybrid Signal indicate a high-risk investment, with a strong upward trend. However, the recent relative divergence change and 7-day rank change suggest an improvement in performance.

The Expected Return is a high 216.00%, indicating a potential for long-term excess return compared to the S&P 500.

Recent news and significant events suggest a mixed outlook for the company, with some news highlighting potential challenges and others forecasting future growth.

Analyst opinions are overwhelmingly positive, with a mean opinion of 'Buy' and a target price of $57.69.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.